Jordan v. Cap Quality Care, Inc.

Superior Court of Maine·Decided March 16, 2009·No. CUMcv-04-248·Unpublished

Opinion

STATE OF MAINE SUPERIOR COURT CUMBERLAND, ss. CIVIL ACTION Docket No. CV -04h4~.r "'''l ,"

) t D - ._.~ '-~- (\ \ -- , ai! ro_! Jc.

.,." .- ..-.. (~' r ,', -..

1

"

NANCY JORDAN, et a1., Plaintiffs,

v. ORDER ON MOTION FOR SUMMARY JUDGMENT

CAP QUALITY CARE INC., et al.,

Defendants.

I. BACKGROUND

Defendant Mallinckrodt Inc. (Mallinckrodt) is a manufacturer of methadone and sells its product to Cap Quality Care Inc., (CAP) a methadone clinic in Westbrook, Maine. CAP sells and dispenses methadone, a synthetic opiod, to individuals on methadone maintenance for opiate addiction.

This case arises out of the death of Seth Jordan (Jordan) on April 14, 2002. He was found dead in his apartment in Portland on that date. A medical examiner determined that he died of methadone poisoning.

The plaintiffs are Seth Jordan's parents, Nancy and Robert Jordan, and Robert Jordan as the Personal Representative of Seth Jordan's estate. The initial complaint was filed April 13, 2004. An amended complaint was filed in November 2004 that alleges twelve claims against Mallinckrodt for Seth Jordan's death. 1 At the time in question, Mallinckrodt was the sole provider of methadone to CAP.

CAP and three CAP employees, Stephen Croteau, Dr. Steven Keefe, and Dr. Marc Shinderman, are also named as defendants in the amended complaint, which alleges separate counts against them that are not pertinent to this motion.

The counts alleged against Mallinckrodt include negligent design defect (Count III); negligent failure to warn (Count V); negligent infliction of emotional distress (Count VII); strict liability

Jordan obtained methadone manufactured by Mallinckrodt from a friend (Patient 1) who had been receiving methadone treatment from CAP for approximately two months prior to the incident. On the Saturday night of Jordan'S death, Patient 1 shared his take-home dose of methadone with Jordan. Since CAP was closed on Sunday, CAP personnel had provided Patient 1 with a take-home dose to self­ administer the following Sunday?

Each sale of methadone from Mallinckrodt to CAP includes an FDA-approved product insert containing warnings and instructions for use. CAP maintains that licensed pharmacists prepare the take-home bottles and each bottle is labeled with the patient's name, address, and daily dose. The label also states that n[f]ederal law prohibits the transfer of this drug to any person other than the patient for whom it is prescribed."

It is not disputed that CAP provides patients with methadone safety information and warnings during the initial orientation, as well as in consent forms, and during counseling sessions with patients. However, the parties have provided contradictory facts as to the extent and efficacy of CAP's orientation and the information sharing with patients that actually occurs. In addition, it is agreed that Mallinckrodt sold methadone to CAP in tablet form, liquid form, and dispersible tablet form, but the parties dispute the form of the particular take-home dose provided to Patient 1 on the date in question. This disputed fact is not relevant to the present motion.

design defect (Count VIII); strict liability failure to warn (Count X); breach of implied warranty of merchantability (Count XII); breach of implied warranty of fitness of particular purpose (Count XIII); wrongful death (Count XVI); punitive damages (Count XVII); vicarious liability (Count XVIII); concert of action liability (Count XIX); and joint enterprise and/ or joint venture (Count XX).

2 At all relevant times, federal and state law permitted methadone maintenance treatment facilities to provide patients with a single take-home dose of methadone for a day that the clinic is closed for business, including Sunday and holidays. 42 c.P.R. § 8.12(i).

While the parties also disagree on whether Patient 1 ever read a product label, it is clear that he disregarded the warnings when he provided Jordan with his methadone. Following Jordan's death, on October 10, 2002, Patient 1 was indicted on charges of manslaughter and furnishing a scheduled drug in connection with Jordan's death. On January 15, 2004 pursuant to a plea bargain, Patient 1 was convicted of furnishing a scheduled drug to Jordan and sentenced to prison.

II. BEFORE THE COURT

Defendant Mallinckrodt has filed a motion for summary judgment on all claims against it, but only provides argument on the negligence (Counts III, V, and VII), strict liability (Count X), design defect (Counts III and VIII), and failure to warn claims (Counts III and X), because the other causes of action against it are merely derivative of the product allegations.

The Jordans argue that Mallinckrodt has ignored the other substantive claims for breach of implied warranty of merchantability; breach of implied warranty of fitness of particular purpose; wrongful death; and emotional distress. However, if the negligent and strict liability design defect and failure to warn claims are dismissed, then the Jordans have no basis to pursue the other claims. All of the other cause of actions against Mallinckrodt require a showing that the methadone is defective or unreasonably dangerous. 3

3 In order to succeed on the other claims, the plaintiff must prove that Mallinckrodt committed some wrongful act or omission. Given the circumstances of the case and the evidence presented, the only wrongful act or omission that a fact finder could reasonably find against Mallinckrodt would require finding Mallinckrodt disseminated a defective or unreasonably dangerous product without adequate warning.

III. DISCUSSION

A. Standard of Review Summary judgment is proper where there exist no genuine issues of material fact such that the moving party is entitled to judgment as a matter of law. M.R.Civ.P.56(c); see also Levine v. R.B.K. Caly Corp., 2001 ME 77 <[ 4, 770 A.2d 653, 655. A genuine issue is raised "when sufficient evidence requires a fact-finder to choose between competing versions of the truth at trial." Parrish v. Wright, 2003 ME 90 <[ 8, 828 A.2d 778, 781. A material fact is a fact that has "the potential to affect the outcome of the suit." Burdzel v. Sobus, 2000 ME 84 <[ 6, 750 A.2d 573, 575. "If material facts are disputed, the dispute must be resolved through fact-finding." Curtis v. Porter, 2001 ME 158 <JI 7, 784 A.2d 18, 22. A party wishing to avoid summary judgment must present a prima facie case for the claim or defense that is asserted. Reliance National Indemnity v. Knowles Industrial Services, 2005 ME 29 <JI 9, 868 A.2d 220, 224-25. At this stage, the facts are reviewed, "in the light most favorable to the nonmoving party." Lightfoot v. Sch. Admin. Dist. No. 35, 2003 ME 24 <JI 6, 816 A.2d 63, 65. B. Design Defect Claims Mallinckrodt argues that it sold methadone to CAP in both liquid and tablet form and the methadone taken by Jordan prior to his death consisted of one 40­ milligram methadone tablet. Mallinckrodt asserts that there is no evidence that Jordan drank or injected a liquid form of methadone. Thus, all allegations concerning liquid methadone are irrelevant to the lawsuit.

The Jordans argue that the 40-milligram tablets given to Jordan were dispersible, meaning they were dissolved in liquid prior to distribution. The affidavit testimony provided by Patient 1 in 2006 and then in 2008 is, thus, contradictory. In his 2006 affidavit, Patient 1 states that he gave Jordan one 40-milligram methadone tablet.

However, in his 2008 affidavit, Patient 1 states that the take-home dose he shared with Jordan was 260 milligrams in liquid form. 4 Patient l's girlfriend at the time in question also provided affidavit testimony in 2008 stating that Patient l's take-home dose was in liquid form. CAP's take-home dose policy requires that "take-home methadone is liquefied and sealed in a tamper-resistant medication bottle."

Free access — add to your briefcase to read the full text and ask questions with AI

Jordan v. Cap Quality Care, Inc., (Me. Super. Ct. 2009).

Jordan v. Cap Quality Care, Inc. (Jordan v. Cap Quality Care, Inc.) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.

Related

Pottle v. Up-Right, Inc.
628 A.2d 672 (Supreme Judicial Court of Maine, 1993)
DiPietro v. Boynton
628 A.2d 1019 (Supreme Judicial Court of Maine, 1993)
Cafazzo v. Central Medical Health Services, Inc.
668 A.2d 521 (Supreme Court of Pennsylvania, 1995)
Cyr v. Giesen
108 A.2d 316 (Supreme Judicial Court of Maine, 1954)
Burdzel v. Sobus
2000 ME 84 (Supreme Judicial Court of Maine, 2000)
Johnson v. Dubois
256 A.2d 733 (Supreme Judicial Court of Maine, 1969)
Parrish v. Wright
2003 ME 90 (Supreme Judicial Court of Maine, 2003)
Williams v. Inverness Corp.
664 A.2d 1244 (Supreme Judicial Court of Maine, 1995)
Morgan v. Kooistra
2008 ME 26 (Supreme Judicial Court of Maine, 2008)
Joy v. Eastern Maine Medical Center
529 A.2d 1364 (Supreme Judicial Court of Maine, 1987)
Bedard v. Greene
409 A.2d 676 (Supreme Judicial Court of Maine, 1979)
Guiggey v. Bombardier
615 A.2d 1169 (Supreme Judicial Court of Maine, 1992)
Dutil v. Burns
674 A.2d 910 (Supreme Judicial Court of Maine, 1996)
Bernier v. Raymark Industries, Inc.
516 A.2d 534 (Supreme Judicial Court of Maine, 1986)
Flanders v. Cooper
1998 ME 28 (Supreme Judicial Court of Maine, 1998)
Merriam v. Wanger
2000 ME 159 (Supreme Judicial Court of Maine, 2000)
Pappas v. Clark
494 N.W.2d 245 (Court of Appeals of Iowa, 1992)
Spickler v. Key Bank of Southern Maine
618 A.2d 204 (Supreme Judicial Court of Maine, 1992)
Carter v. Williams
2002 ME 50 (Supreme Judicial Court of Maine, 2002)
Curtis v. Porter
2001 ME 158 (Supreme Judicial Court of Maine, 2001)